27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
These results agree with a persistent inflammatory status in AD, reinforcing the hypothesis of a progressive impairment of the immune response in this disorder and suggesting that monocytes may be good targets to study the progression from MCI to AD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia, is a critical global public health challenge with no effective pharmacological treatments. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over a median follow-up of 3.26 years, 321 participants converted to AD. 5 key findings →
Participants: 762 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Exposure to accelerated epigenetic aging was significantly associated with a higher risk of transition from NC to MCI as well as progression from MCI to dementia. 5 key findings →
Participants: 2,671 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 2056 papers related to machine learning in patients with MCI were retrieved from the Wo SCC database. 5 key findings →
Participants: 2,056 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A network neuroscience perspective can significantly advance the understanding of neurodegenerative disorders, particularly frontotemporal dementia (FTD). 5 key findings →
Participants: 28 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
could serve as potential biomarkers for NAFLD-associated mild cognitive impairment; 3) bacterial metabolic functions involved in sugar degradation and the breakdown of tryptophan and glutamate were downregulated and linked to CXCL13 plasma levels and neuroinflammation; 4) correlations between SCFA concentrations disappeared with liver disease and cognitive impairment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Patients with hearing impairment presented slightly altered results on cognitive tests, typical of a mild cognitive impairment. 4 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment progresses slowly and may be reversible, providing a window of opportunity for intervention before it progresses to Alzheimer's disease, at which point treatments, at best, ameliorate symptoms with little efficacy towards delaying disease progression. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Mild Cognitive Impairment (MCI) is a transitional stage between normal aging and Alzheimer's disease. 5 key findings →
Participants: 476 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
SCD participants were older, had fewer years of education, more depressive symptoms, and more subjective cognitive complaints than CU participants. 4 key findings →
Participants: 315 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The development of non-pharmacological treatment approaches is supported by evidence that addressing key modifiable risk factors may prevent or delay up to 45% of dementia cases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Age and years of education (YOE) were identified as independent clinical risk factors for PD-MCI. 5 key findings →
Participants: 1,316 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 800 questionnaires were sent out in this survey, and 778 were effectively collected, with an effective recovery rate of 97.25%. 5 key findings →
Design: cross-sectional Participants: 82 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundStructural changes in medial temporal lobes including the fusiform gyrus, a critical area in face recognition, precede the progression of amnestic mild cognitive impairment (aMCI) to Alzheimer's disease (AD). 2 key findings →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Two distinct subtypes emerged. Subtype 1 (n = 63) features localized supra-normal gray matter volume deviations in dorsolateral prefrontal regions, elevated free water indicating microstructural disruption, executive dysfunction, and transcriptional enrichment in metabolic dysfunction and neurodegenerative pathways. 5 key findings →
Participants: 115 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The growing prevalence of dementia emphasizes the need for effective prevention strategies. 4 key findings →
Participants: 289 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For the interim analysis as of October 2024, the results of the MCI study arm are reported (n=42). 5 key findings →
Participants: 42 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
White matter hyperintensities (WMHs) and cerebral β-amyloid (Aβ) have been characterized as clinically significant biomarkers associated with greater cognitive decline and incidence of Alzheimer's Disease (AD) dementia. 3 key findings →
Participants: 523 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Tauopathies are neurodegenerative disorders characterized by the accumulation of abnormal tau protein leading to cognitive and/or motor dysfunction. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The perforant pathway projection from layer II of the entorhinal cortex to the hippocampal dentate gyrus is especially important for long-term memory formation, and is preferentially vulnerable to developing a degenerative tauopathy early in Alzheimer's disease (AD) that may spread over time trans-synaptically. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Virtual Reality (VR) has emerged as a promising tool in many domains of therapy and rehabilitation, and has recently attracted the attention of researchers and clinicians working with elderly people with MCI, Alzheimer's disease and related disorders. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Though both traditional and computer-based cognitive intervention programmes seem to be effective, the computer-based ones present more advantages: 1) they could individualize the programme tailored to the patient's neuropsychological pattern and needs. 2) they permit the user to make an immediate objective comparison with data collected earlier and thus help in setting up a systematic training plan by providing instant value-free feedback. 3) they offer a possibility of a widescale dissemination. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Physical and cognitive idleness constitute significant risk factors for the clinical manifestation of age-related neurodegenerative diseases. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Aging is associated with cognitive decline, yet this does not prevent older adults from finding ways to compensate for age-related deficits. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
9 of the 2,141 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →